Sugi Predict

Sugi Predict / Compounds / SCHEMBL2592865

SCHEMBL2592865

SCHEMBL2592865

COc1nc(NC(=O)O)cc(C)c1C#N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 11/20 0.59
▸ MAPK9 P45984 9/20 0.59
▸ RECQL P46063 2/20 0.56
▸ PRKD3 O94806 4/20 0.43
▸ MAP4K4 O95819 2/20 0.43
▸ MAP4K2 Q12851 2/20 0.43
▸ PKN2 Q16513 2/20 0.43
▸ MAPK10 P53779 2/20 0.43
▸ PRKD2 Q9BZL6 1/20 0.43
▸ STK17A Q9UEE5 1/20 0.43
▸ TSHR P16473 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ MAP4K5 Q9Y4K4 1/20 0.41
▸ SQOR Q9Y6N5 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL553429 0.81 MAPK8 (0.41) MAPK8MAPK9RECQLPRKD3MAP4K4
SCHEMBL7897544 0.79 L3MBTL1 (0.50) MAPK8MAPK9PRKD3MAP4K4MAP4K2
SCHEMBL2592807 0.79 RECQL (0.59) MAPK8MAPK9RECQLTSHRPOLB
SCHEMBL19068769 0.78 RECQL (0.58) MAPK8MAPK9RECQLTSHRPOLB
SCHEMBL2594001 0.76 RECQL (0.52) MAPK8MAPK9RECQLMAPK10TSHR
SCHEMBL1145443 0.74 MAPK8 (1.00) MAPK8MAPK9PRKD3MAP4K4MAP4K2
SCHEMBL2673753 0.74 RECQL (0.71) RECQLTSHRPOLBMAPK1GAA
SCHEMBL2595112 0.73 MAPK8 (0.40) MAPK8MAPK9PRKD3MAP4K4MAP4K2
SCHEMBL18185851 0.73 MAPK8 (0.43) MAPK8MAPK9PRKD3MAP4K4MAP4K2
SCHEMBL5377959 0.73 RECQL (1.00) MAPK8MAPK9RECQLTSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2019-11-19 — — US disclosed
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2018-07-26 — — US disclosed
US-9956210-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-3246027-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER GlaxoSmithKline LLC (US) 2017-11-22 — — EP disclosed
US-9649307-B2 Indoles GLAXOSMITHKLINE LLC (US) 2017-05-16 — — US disclosed
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2017-04-06 — — US disclosed
US-20160296518-A1 INDOLES GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
EP-2646020-B1 INDOLES GLAXOSMITHKLINE LLC (US) 2016-09-21 — — EP disclosed
US-9446041-B2 Method of treatment GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2016-09-20 — — US disclosed
EP-2773754-B1 Compounds for use in the treatment of T-cell mediated diseases GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-08-03 — — EP disclosed
US-20130345200-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2013-12-26 — — US disclosed
WO-2013173441-A2 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-11-21 — — WO disclosed
EP-2646020-A1 INDOLES GlaxoSmithKline LLC (US) 2013-10-09 — — EP disclosed
US-20130245016-A1 INDOLES GLAXOSMITHKLINE LLC 2013-09-19 — — US disclosed
US-8536179-B2 Indoles GLAXOSMITHKLINE LLC (US) 2013-09-17 — — US disclosed
WO-2013067296-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) 2013-05-10 — — WO disclosed
EP-2566327-A1 INDOLES GlaxoSmithKline LLC (US) 2013-03-13 — — EP disclosed
US-20130053397-A1 INDOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
WO-2012075080-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2012-06-07 — — WO disclosed
WO-2011140324-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245016-A1 INDOLES IDO1, IDO2, INMT MAPK8 3764/4885MAPK9 3122/4885RECQL 1489/4885
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 MAPK8 1808/4885MAPK9 1370/4885RECQL 3966/4885
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 MAPK8 1808/4885MAPK9 1370/4885RECQL 3966/4885
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors EZH2, EZH1, BMI1 MAPK8 1808/4885MAPK9 1370/4885RECQL 3966/4885
US-20130345200-A1 INDOLES IDO1, IDO2, INMT MAPK8 3764/4885MAPK9 3122/4885RECQL 1489/4885
US-20130053397-A1 INDOLES IDO1, IDO2, INMT MAPK8 3796/4885MAPK9 3162/4885RECQL 1597/4885
US-20160296518-A1 INDOLES IDO1, IDO2, INMT MAPK8 3764/4885MAPK9 3122/4885RECQL 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.